연속혈당측정시스템(CGMS) 시장 규모, 점유율, 동향, 예측 : 컴포넌트, 인구통계, 최종사용자, 지역별(2025-2033년)

The global continuous glucose monitoring systems market size was valued at USD 7.04 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 10.92 Billion by 2033, exhibiting a CAGR of 4.75% from 2025-2033. North America currently dominates the market, holding a market share of over 38.7% in 2024. The increasing awareness and adoption of CGM devices, rising prevalence of diabetes, significant technological advancements in CGM devices, and ongoing shift towards preventive healthcare are some of the factors boosting the continuous glucose monitoring systems market share.

Continuous glucose monitoring systems (CGMS) are technologically advanced devices that automatically track blood glucose levels. They consist of a transmitter-integrated sensor that functions through a transcutaneous or subcutaneous route to continuously measure the glucose concentration in interstitial fluid. The transmitter then sends the information to a wireless monitor that can be clipped to clothes. Continuous glucose monitoring systems assist in providing a complete profile of diabetes, alerting highs and lows of blood sugar levels, detecting patterns, and increasing patient insights regarding physical activity, medication choices, food portions and stress. As compared to conventional glucose monitoring devices, CGMS are prick-free as they can be placed over the skin, thus aiding in providing real-time information in a quick and painless fashion.

Continuous Glucose Monitoring Systems Market Trends:

The rising geriatric population across the globe that are more susceptible to developing diabetes is creating a positive outlook for the market. CGMS is commonly used for measuring glucose and insulin level in the body, which further sounds an alarm if it drops or rises to a dangerous level. In line with this, the widespread product utilization to identify hypoglycemia and hyperglycemic situations in real-time is favoring the market growth. Moreover, significant improvements and new technological advancements in CGMS that aid in detecting glycated hemoglobin (Hb1ac) in patients with diabetes are providing a considerable boost to the market growth. Additionally, the integration of artificial pancreas device systems with CGMS technology to pump insulin and administer optimum dosage to manage the blood sugar levels of patients is positively impacting the market growth. Apart from this, the introduction of non-invasive CGMS devices as a convenient alternative, extensive research and development (R&D) activities and the increasing demand for less or minimally invasive diagnostic tools are anticipated to drive the market further toward growth.

Key Market Segmentation:

Breakup by Component:

• Sensors
• Transmitters and Receivers
• Integrated Insulin Pumps

Breakup by Demographics:

• Child Population (<=14 years)
• Adult Population (>14 years)

Breakup by End User:

• Clinics and Diagnostics Centers
• ICUs
• Home Healthcare

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc. and Waveform Technologies Inc.

Key Questions Answered in This Report

• 1.How big is the continuous glucose monitoring systems market?
• 2.What is the future outlook of continuous glucose monitoring systems market?
• 3.What are the key factors driving the continuous glucose monitoring systems market?
• 4.Which region accounts for the largest continuous glucose monitoring systems market share?
• 5.Which are the leading companies in the global continuous glucose monitoring systems market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Continuous Glucose Monitoring Systems Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Component

• 6.1 Sensors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Transmitters and Receivers
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Integrated Insulin Pumps
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Demographics

• 7.1 Child Population (<=14 years)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Adult Population (>14 years)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End User

• 8.1 Clinics and Diagnostics Centers
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 ICUs
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Home Healthcare
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 A. Menarini Diagnostics S.r.l.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Abbott Laboratories
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 DexCom Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 F. Hoffmann-La Roche AG
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Glysens Incorporated
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 LifeScan Inc. (Johnson & Johnson)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 SWOT Analysis
  • 14.3.7 Medtronic PLC
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Medtrum Technologies Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Nemaura Medical Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Novo Nordisk A/S
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Senseonics Holdings Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
  • 14.3.12 Waveform Technologies Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio